Separate names with a comma.
All of what you've said is very true. In their defense though, Otonomy did release Otiprio for swimmer's ear. They later sold it.
Let's hope so!
Invest that in fundamental research instead, like Hyperacusis Research.
It didn't. The higher dosage trials failed (and so did their tinnitus drug, OTO-313).
Otonomy Reports Positive Top-Line Results from Phase 2a...
Then nothing happens with this drug. OTO-413 is there for that.
It is common knowledge that CEOs take business decisions based on mails by random people.
Otonomoy's OTO-6XX is aimed at hair cell "repair" instead of regeneration. Unfortunately the company is in a really bad shape so I don't know if...
If you regenerate the hair cell, the synapse restores on its own.
Around the 29:00 mark.
Reading your post reminded me of Bryan Pollard. He also had an engineering approach when founding Hyperacusis Research. May he rest in peace....
I'm gonna nitpick here lol, but AlphaFold's breakthrough is in protein structure predition, not protein folding.
Which one of those have hyperacusis?
She finished second.
Good point :)
If you would actually read Otonomy's press releases, you would have known this is not the case:
Otonomy intends to initiate a dose-ranging Phase...
They have already stated multiple times that they will do a full Phase 2 first.